Ocrelizumab
- Product Name
- Ocrelizumab
- CAS No.
- 637334-45-3
- Chemical Name
- Ocrelizumab
- Synonyms
- Ocrelizumab;Ocrelizumab (anti-CD20);Research Grade Ocrelizumab;Research Grade Ocrelizumab(DHC90702)
- CBNumber
- CB23039319
- Molecular Formula
- C19H16N2O5
- Formula Weight
- 0
- MOL File
- Mol file
Ocrelizumab Property
- form
- Liquid
- color
- Colorless to light yellow
Safety
- Hazardous Substances Data
- 637334-45-3(Hazardous Substances Data)
Ocrelizumab Chemical Properties,Usage,Production
History
The development of Ocrelizumab, sold under the brand name Ocrevus, starts with rituximab, another monoclonal antibody (MAb) that was developed for the treatment of autoimmune disorders and was approved for the treatment of CD20-positive follicular non-Hodgkin lymphoma in 1994. However, rituximab is a chimeric MAb and is immunogenic in humans, and the manufacturer decided to focus on the similar but fully humanized MAb, ocrelizumab, for multiple sclerosis instead. It was granted approval by the U.S. Food and Drug Administration (FDA) in 2017 as the first treatment indicated for both relapsing and primary progressive forms of multiple sclerosis.Ocrelizumab has also been approved by the European Medicines Agency.
Uses
Treatment of rheumatoid arthritis.
in vivo
Ocrelizumab (7.5 mg/kg; once daily; 18 days; s.c. or i.v.) inhibits lesions in multiple sclerosis mice by inducing B cell exhaustion through antibody dependent cytotoxicity (ADCC)[1]. Ocrelizumab (50 μg; repeat administration on days 7, 14, and 21; i.v.) can reduce B and T cells in the blood, lymph nodes, and spleen of C57BL/6 mice[2].
| Animal Model: | HuCD20 mice with chronic DTH-TLS lesions[1]. |
| Dosage: | 7.5 mg/kg |
| Administration: | Subcutaneous injection (s.c.) or intravenous injection (i.v.); once daily; 18 days; initiated on Days 63, 70 and 75 post lesion induction |
| Result: | Reduced the number of CD19+ cells and MS like lesions in the spleen and lymph nodes of mice. |
| Animal Model: | C57BL/6 mice [2]. |
| Dosage: | 50 μg |
| Administration: | Intravenous injection (i.v.); repeat administration on days 7, 14, and 21 |
| Result: | Reduced the total CD19+ B cells and CD4, CD8 T cells in the blood, spleen, and LN. |